相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regulation of Copper and Iron Homeostasis by Metal Chelators: A Possible Chemotherapy for Alzheimer's Disease
Anne Robert et al.
ACCOUNTS OF CHEMICAL RESEARCH (2015)
The Epidemiology of Dementia and Alzheimer Disease in Portugal: Estimations of Prevalence and Treatment-Costs
Isabel Santana et al.
ACTA MEDICA PORTUGUESA (2015)
Alzheimer's Association Report 2015 Alzheimer's disease facts and figures
ALZHEIMERS & DEMENTIA (2015)
Inhibition of c-Jun N-Terminal Kinase Activation Reverses Alzheimer Disease Phenotypes in APPswe/PS1dE9 Mice
Qiong Zhou et al.
ANNALS OF NEUROLOGY (2015)
Emerging drug targets for A and tau in Alzheimer's disease: a systematic review
Sophie West et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer's Disease
Robert J. Baranello et al.
CURRENT ALZHEIMER RESEARCH (2015)
Antibody-targeted drugs and drug resistance-Challenges and solutions
LeeRon Shefet-Carasso et al.
DRUG RESISTANCE UPDATES (2015)
Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Treatment Effect
Marina Miguel-Alvarez et al.
DRUGS & AGING (2015)
Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation
Julia R. Clarke et al.
EMBO MOLECULAR MEDICINE (2015)
Masitinib for the treatment of mild to moderate Alzheimer's disease
Jaume Folch et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Stabilization of Nontoxic Aβ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease
Timothy M. Ryan et al.
JOURNAL OF NEUROSCIENCE (2015)
The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans
Patrick C. May et al.
JOURNAL OF NEUROSCIENCE (2015)
Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline
Sarah Gourmaud et al.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2015)
Hypothesis of Endogenous Anticholinergic Activity in Alzheimer's Disease
Kimiko Konishi et al.
NEURODEGENERATIVE DISEASES (2015)
Immunotherapeutic Approaches for Alzheimer's Disease
Thomas Wisniewski et al.
NEURON (2015)
Drug development for tauopathies
F. Grueninger
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2015)
Neuronal stress signaling and eIF2α phosphorylation as molecular links between Alzheimer's disease and diabetes
Mychael V. Lourenco et al.
PROGRESS IN NEUROBIOLOGY (2015)
Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death
Daniela Rossi
PROGRESS IN NEUROBIOLOGY (2015)
Post-mortem analysis of neuroinflammatory changes in human Alzheimer's disease
Diego Gomez-Nicola et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease
Fernanda G. De Felice et al.
FRONTIERS IN AGING NEUROSCIENCE (2015)
Masitinib for the treatment of mild to moderate Alzheimer's disease
Jaume Folch et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Nerve Growth Factor Gene Therapy Activation of Neuronal Responses in Alzheimer Disease
Mark H. Tuszynski et al.
JAMA NEUROLOGY (2015)
Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau
Katja Hochgraefe et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
Drug Access to the Central Nervous System in Alzheimer's Disease: Preclinical and Clinical Insights
Dharmini C. Mehta et al.
PHARMACEUTICAL RESEARCH (2015)
Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease
Claude M. Wischik et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia
Amy Claxton et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease
Thomas C. Baddeley et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Design, Synthesis, and Evaluation of Multitarget-Directed Selenium-Containing Clioquinol Derivatives for the Treatment of Alzheimer's Disease
Zhiren Wang et al.
ACS CHEMICAL NEUROSCIENCE (2014)
On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis
Michael A. Castello et al.
AGEING RESEARCH REVIEWS (2014)
Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease
Sergio T. Ferreira et al.
ALZHEIMERS & DEMENTIA (2014)
The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease
David A. Drachman
ALZHEIMERS & DEMENTIA (2014)
Emerging Therapeutics for Alzheimer's Disease
Karen Chiang et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
The dendritic hypothesis for Alzheimer's disease pathophysiology
J. Nicholas Cochran et al.
BRAIN RESEARCH BULLETIN (2014)
Altered Expression of Diabetes-Related Genes in Alzheimer's Disease Brains: The Hisayama Study
Masaaki Hokama et al.
CEREBRAL CORTEX (2014)
Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?
Ada M. Tata et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2014)
CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloid-beta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro
Nicole Ronsisvalle et al.
CURRENT ALZHEIMER RESEARCH (2014)
Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease
Fernanda G. De Felice et al.
DIABETES (2014)
Serotonergic Therapies for Cognitive Symptoms in Alzheimer's Disease: Rationale and Current Status
Maria J. Ramirez et al.
DRUGS (2014)
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
Francesco Panza et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Investigational drugs in Alzheimer's disease: current progress
Camryn Berk et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease
Khalid Iqbal et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
Francesco Panza et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice
Helmut Jacobsen et al.
JOURNAL OF NEUROSCIENCE (2014)
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
David Wilkinson et al.
LANCET NEUROLOGY (2014)
Targeting the β secretase BACE1 for Alzheimer's disease therapy
Riqiang Yan et al.
LANCET NEUROLOGY (2014)
Dietary and lifestyle guidelines for the prevention of Alzheimer's disease
Neal D. Barnard et al.
NEUROBIOLOGY OF AGING (2014)
Nutrition and the brain: what advice should we give?
James K. Cooper
NEUROBIOLOGY OF AGING (2014)
Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition
Brittany L. Adler et al.
NEUROBIOLOGY OF AGING (2014)
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Douglas Galasko et al.
NEUROLOGY (2014)
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease
Tara L. Spires-Jones et al.
NEURON (2014)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity
Kent E. S. Matlack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Fyn kinase inhibition as a novel therapy for Alzheimer's disease
Haakon B. Nygaard et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model
Eva Kontsekova et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
Kelly Willemijn Menting et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?
Wei Qiao Qiu et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Alzheimer disease immunotherapeutics Then and now
Harashish Jindal et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Physiological and pathological phosphorylation of tau by Cdk5
Taeko Kimura et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2014)
Rational heterodoxy: Cholesterol reformation of the amyloid doctrine
Michael A. Castello et al.
AGEING RESEARCH REVIEWS (2013)
Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects
Bruno P. Imbimbo et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2013)
Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex
T. L. Wallace et al.
BIOCHEMICAL PHARMACOLOGY (2013)
TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer's β-Amyloid Oligomers in Mice and Monkeys
Mychael V. Lourenco et al.
CELL METABOLISM (2013)
Intranasal Insulin as a Treatment for Alzheimer's Disease: A Review of Basic Research and Clinical Evidence
Jessica Freiherr et al.
CNS DRUGS (2013)
CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study
Joel Ross et al.
CURRENT ALZHEIMER RESEARCH (2013)
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
Haythum O. Tayeb et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Connecting Type 2 diabetes to Alzheimer's disease
Fernanda G. De Felice
EXPERT REVIEW OF NEUROTHERAPEUTICS (2013)
Protection against the synaptic targeting and toxicity of Alzheimer's-associated A beta oligomers by insulin mimetic chiro-inositols
Jason Pitt et al.
FASEB JOURNAL (2013)
Alzheimer's disease and insulin resistance: translating basic science into clinical applications
Fernanda G. De Felice
JOURNAL OF CLINICAL INVESTIGATION (2013)
MER5101, a Novel Aβ1-15:DT Conjugate Vaccine, Generates a Robust Anti-Aβ Antibody Response and Attenuates Aβ Pathology and Cognitive Deficits in APPswe/PS1ΔE9 Transgenic Mice
Bin Liu et al.
JOURNAL OF NEUROSCIENCE (2013)
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard Dodel et al.
LANCET NEUROLOGY (2013)
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nutritional approaches in the risk reduction and management of Alzheimer's disease
Weiqian Mi et al.
NUTRITION (2013)
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease
Dijana Novakovic et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Importance and management of micronutrient deficiencies in patients with Alzheimer's disease
Brbara Rita Cardoso et al.
CLINICAL INTERVENTIONS IN AGING (2013)
Are tau aggregates toxic or protective in tauopathies?
Catherine M. Cowan et al.
FRONTIERS IN NEUROLOGY (2013)
Deregulated Cdk5 Activity Is Involved in Inducing Alzheimer's Disease
Varsha Shukla et al.
ARCHIVES OF MEDICAL RESEARCH (2012)
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Vladimir Coric et al.
ARCHIVES OF NEUROLOGY (2012)
Alzheimer Mechanisms and Therapeutic Strategies
Yadong Huang et al.
CELL (2012)
Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men
Gary Tong et al.
CLINICAL DRUG INVESTIGATION (2012)
A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects
Randy Dockens et al.
CLINICAL PHARMACOKINETICS (2012)
Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimer's Disease Treatment
Orly Weinreb et al.
CURRENT DRUG TARGETS (2012)
Is RAGE still a therapeutic target for Alzheimer's disease?
Richard J. Deane
FUTURE MEDICINAL CHEMISTRY (2012)
The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers
David Wallon et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bernd Bohrmann et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice
Bin Zhang et al.
JOURNAL OF NEUROSCIENCE (2012)
JNK3 Perpetuates Metabolic Stress Induced by Aβ Peptides
Sung Ok Yoon et al.
NEURON (2012)
GSK3 beta inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons
Aurelio Vazquez de la Torre et al.
PHARMACOLOGICAL RESEARCH (2012)
Neurotoxicity of Amyloid β-Protein: Synaptic and Network Dysfunction
Lennart Mucke et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Trafficking and Proteolytic Processing of APP
Christian Haass et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
Darin Jaturapatporn et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
Paul S. Aisen et al.
ARCHIVES OF MEDICAL SCIENCE (2011)
γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Bruno P. Imbimbo et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
PPAR gamma Co-Activator-1 alpha (PGC-1 alpha) Reduces Amyloid-beta Generation Through a PPAR gamma-Dependent Mechanism
Loukia Katsouri et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
Fyn, a Potential Target for Alzheimer's Disease
Kai Yang et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
Christoph Wiessner et al.
JOURNAL OF NEUROSCIENCE (2011)
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Tomohiko Sato et al.
NEUROBIOLOGY OF AGING (2011)
Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimitotic drug paclitaxel
Or A. Shemesh et al.
NEUROBIOLOGY OF DISEASE (2011)
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2011)
Association of Alzheimer disease pathology with abnormal lipid metabolism The Hisayama Study
T. Matsuzaki et al.
NEUROLOGY (2011)
Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation
John M. Ringman et al.
NEUROSCIENCE LETTERS (2011)
Identifying and validating biomarkers for Alzheimer's disease
Christian Humpel
TRENDS IN BIOTECHNOLOGY (2011)
The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease
Robert Vassar et al.
ALZHEIMERS RESEARCH & THERAPY (2011)
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
Francois Piette et al.
ALZHEIMERS RESEARCH & THERAPY (2011)
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Michael Gold et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2010)
Can Nutrients Prevent or Delay Onset of Alzheimer's Disease?
Patrick J. G. H. Kamphuis et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model
Niall M. Corcoran et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Measurement of anti-beta amyloid antibodies in human blood
Paul Szabo et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Effects of Long-Term Pioglitazone Treatment on Peripheral and Central Markers of Aging
Eric M. Blalock et al.
PLOS ONE (2010)
Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models
Janet van Eersel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia
Weiping Qin et al.
ARCHIVES OF NEUROLOGY (2009)
Effect of tramiprosate in patients with mild-to-moderate alzheimer's disease: Exploratory analyses of the MRI sub-group of the alphase study
S. Gauthier et al.
JOURNAL OF NUTRITION HEALTH & AGING (2009)
Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests
K. A. Bates et al.
MOLECULAR PSYCHIATRY (2009)
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Norman R. Relkin et al.
NEUROBIOLOGY OF AGING (2009)
A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease
Patrizio Pasqualetti et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2009)
Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease
Natalia N. Nalivaeva et al.
CURRENT ALZHEIMER RESEARCH (2008)
The role of the cell surface LRP and soluble LRP in blood-brain barrier a clearance in Alzheimer's Disease
R. Deane et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice
Andreas Muhs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The role of CDK5/P25 formation/inhibition in neurodegeneration
Antoni Camins et al.
DRUG NEWS & PERSPECTIVES (2006)
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease
M. E. Risner et al.
PHARMACOGENOMICS JOURNAL (2006)
Understanding molecular mechanisms of proteolysis in Alzheimer's disease: Progress toward therapeutic interventions
M Higuchi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?
PT Francis et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
Targeting JNK3 for the treatment of neurodegenerative disorders
L Resnick et al.
DRUG DISCOVERY TODAY (2004)
Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis
EG Jorda et al.
NEUROPHARMACOLOGY (2003)
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
JL Eriksen et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze
ML Woolley et al.
NEUROPHARMACOLOGY (2001)
分享论文
